Has Samir Kapadia, MD received payments from drug or device companies?

Yes. Drug and device makers reported $37,090 in general payments to Samir Kapadia, MD across 150 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samir Kapadia, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samir Kapadia, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samir Kapadia, MD

Cardiovascular Disease · Cleveland, OHNPI 1356438014

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $26,393 of the $37,090 with a category attached, or 71.2%. 15 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 33.9% of the total. Reporting peaked in 2019 at $17,660 and has fallen 96.4% since, to $639 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,090in general payments, 2019–2025

Across 150 payments — averaging $247.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Siemens Medical Solutions USA, Inc.$13K
Abbott$7K
Admedus Corporation$6K
Boston Scientific$5K
Edwards Lifesciences$3K
Ancora Heart, Inc.$1K
plus $2K from 9 others

$11,027,933in research payments, 2019–2025

Across 628 payments — averaging $17,560 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$5.7M
Edwards Lifesciences$4.1M
Abbott$1M
Siemens Medical Solutions USA, Inc.$154K
Biotronik Inc.$30K
Livanova USA, Inc.$17K
plus $12K from 2 others

What the payments were for

Speaking & faculty fees$6,00016%
Travel & lodging$26,39371%
Food & beverage$4,69713%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Siemens Medical Solutions USA, Inc.	24	$12,576
Abbott	47	$6,741
Admedus Corporation	2	$6,000
Boston Scientific	24	$5,201
Edwards Lifesciences	25	$2,651
Ancora Heart, Inc.	5	$1,491
Medtronic	13	$1,355
Cardiac Dimensions, Inc.	2	$411
Penumbra, Inc.	1	$235
Impulse Dynamics (USA) Inc.	1	$233
Bayer	1	$91
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$39
Livanova USA, Inc.	1	$28
Argon Medical Devices, Inc.	1	$23
Omeros Corporation	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Artis Q$6,143
Multix Impact$5,388
Mitra Clip system$3,845
GENERAL - THERAPIES$3,243
AccuCinch$1,401
Tendyne Mitral Valve System$1,002
CLINICAL TRIAL PRODUCT$797
GENERAL - STRUCTURAL HEART$750
OPTIMIZER$467
MitraClip$352
ARTIS icono biplane$260
Indigo System$235
Artis Q.zen$153
Sentinel$150
COREVALVE EVOLUT R$127
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$126

How this compares

$37,090 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio →

Medicare billing

Part B allowed, 2024

$147,755

Medicare patients

241

Services billed

468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	60	$73,712
EliquisApixaban	64	$67,089
Metoprolol Succinate	61	$1,231
Omega-3 Acid Ethyl Esters	11	$1,081
Ezetimibe	12	$887
ClopidogrelClopidogrel Bisulfate	67	$755
Losartan Potassium	30	$520
Atorvastatin Calcium	51	$503
Rosuvastatin Calcium	22	$434
Amlodipine Besylate	22	$140
Isosorbide Mononitrate ErIsosorbide Mononitrate	20	$127
Spironolactone	16	$90
Furosemide	24	$85
Lisinopril	19	$33
Amoxicillin	11	$7

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Cleveland

Guilherme AttizzaniCleveland$1.3M
Abraham LincoffCleveland$369K
Oussama WazniCleveland$367K
Ian NeelandCleveland$329K
Mazen HannaCleveland$208K
Brian HoitCleveland$207K
Steven NissenCleveland$149K
Daniel CantillonCleveland$140K
Serge HarbCleveland$134K
Wael JaberCleveland$124K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →